Monte Rosa Therapeutics (GLUE) Net Equity Issued and Repurchased (2020 - 2025)
Monte Rosa Therapeutics (GLUE) posted quarterly Net Equity Issued and Repurchased of $24.2 million for Q4 2025, up 270.34% quarter-over-quarter from $6.5 million in Q4 2022.
Monte Rosa Therapeutics (GLUE) Net Equity Issued and Repurchased (2020 - 2025) Analysis & Trends
Monte Rosa Therapeutics' Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $24.2 million for Q4 2025.
- In Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $24.2 million; the TTM figure through Dec 2025 stood at $24.2 million (changed N/A YoY), while the FY2025 annual figure was $24.2 million, up 2468.86% from the prior year.
- Net Equity Issued and Repurchased for Q4 2025 stood at $24.2 million, up from $6.5 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $143.0 million in Q1 2021, with the low at -$143.0 million in Q4 2021.
- The 3-year median for Net Equity Issued and Repurchased is $13.5 million (2022), against an average of $8.9 million.
- Peak annual rise in Net Equity Issued and Repurchased reached 104.58% in 2022, while the deepest fall reached 104.58% in 2022.
- Monte Rosa Therapeutics' Net Equity Issued and Repurchased stood at -$143.0 million in 2021, then soared by 104.58% to $6.5 million in 2022, then jumped by 270.34% to $24.2 million in 2025.
- Business Quant data shows GLUE's Net Equity Issued and Repurchased at $24.2 million in Q4 2025, $6.5 million in Q4 2022, and $13.5 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 24.25 Mn |
| Dec 31, 2025 | 24.25 Mn |
| Dec 31, 2022 | 6.55 Mn |
| Dec 31, 2022 | 6.55 Mn |
| Sep 30, 2022 | 13.51 Mn |
| Sep 30, 2022 | 13.51 Mn |
| Dec 31, 2021 | -143.00 Mn |
| Dec 31, 2021 | -143.00 Mn |
| Mar 31, 2021 | 143.00 Mn |
| Mar 31, 2021 | 143.00 Mn |
| Sep 30, 2020 | 48.00 Mn |
| Sep 30, 2020 | 48.00 Mn |